吲哚布芬治疗冠心病合并非瓣膜性心房颤动的效果观察

Observation on the Eff ect of Indobufen in the Treatment of Coronary Heart Disease Combined with Non valvular Atrial Fibrillation

进行冠心病合并非瓣膜性心房颤动治疗中应用吲哚布芬的效果探究.选取2021年5月-2021年10月内收治的71例冠心病合并非瓣膜性心房颤动患者为研究对象,并应用随机分配法将其分为对照组和观察组两组,对照组37例患者应用阿司匹林治疗,观察组34例患者应用吲哚布芬治疗.比较两组患者治疗结果.结果表明,治疗后,观察组脑卒中发生率更低、心肌缺血改善率更高、胃肠道反应率更低、血小板减少率更低、出血率更低(P<0.05);治疗后,观察组各项生活质量评分更高(P<0.05);观察组B型利尿钠肽更低、N末端B型利尿钠肽原更低、6 min步行试验距离更长、心功能分级更低(P<0.05).研究发现,应用吲哚布芬治疗冠心病合并非瓣膜性心房颤动,有利于控制相关不良事件发生风险,改善患者的生活质量、心功能指标、左心室功能指标,减轻炎症反应.

Exploring the efficacy of using indoprofen in the treatment of coronary heart disease combined with non valvular atrialfibrillation.71 patients with coronary heart disease complicated with non valvular atrialfibrillation admitted between May 2021 and October 2021 were selected as the study subjects.They were randomly assigned into a control group and an observation group,with 37 patients in the control group treated with aspirin and 34 patients in the observation group treated with indolebufen.Compare the treatment outcomes between two groups of patients.The results showed that after treatment,the observation group had a lower incidence of stroke,higher improvement rate of myocardial ischemia,lower gastrointestinal response rate,lower thrombocytopenia rate,and lower bleeding rate(P<0.05);After treatment,the observation group had higher scores of various quality of life(P<0.05);The observation group had lower levels of B-type natriuretic peptide,N-terminal B-type natriuretic peptide precursor,longer 6-minute walking distance,and lower heart function grading(P<0.05).Research has found that the use of indobufen in the treatment of coronary heart disease combined with non valvular atrialfibrillation is beneficial for controlling the risk of related adverse events,improving the quality of life,heart function indicators,left ventricular function indicators of patients,and reducing inflammatory reactions.